Erin George, MD

Funded by the 2025 Kay Yow Cancer Fund Final Four Research Award

Ovarian cancer is hard to treat. Most patient’s cancer comes back after standard treatment. Once the disease is back it is more difficult to treat and patients will eventually die from it. Chemotherapy can also cause direct harm to the body. This can make patients delay treatment, stop it altogether, or lower their doses. It can also harm the good bacteria in the gut, which is important for how well treatments work. Our goal is to come up with new ways to predict, prevent, and manage these harmful effects. We also want to develop new therapies that can lead to complete and lasting responses, increasing chances of cure right from the start. To reach this goal we will use mathematical modeling. This will allow us to test many treatments quickly, which cannot be done with traditional laboratory methods. First, we will use patient blood samples to predict the risk of toxicity, helping doctors know when to change or pause treatment. Next, we will use math modeling to find the best combinations of new targeted therapies. Finally, we will reduce the harmful effects of chemotherapy on the gut using math modeling to improve how well those therapies work. This research could change how we treat cancer. It may lead to complete tumor response and better chances for a cure.

Sita Kugel, PhD

Funded by the V Foundation Wine Celebration in honor of Mike “Coach K” and Mickie Krzyzewski

Pancreatic cancer is the third leading cause of cancer death in the United States. Treatments have changed very little in recent years. One challenge is that there are different “subtypes” of pancreatic cancer, so tailored therapies are desperately needed. Our lab found that drugs that block a protein called cyclin-dependent kinase 7 (CDK7) can kill the basal subtype, which is the most lethal. It makes up a quarter of pancreatic tumors and has the worst overall survival. We propose to study a drug that blocks CDK7 in patients with early-stage pancreatic cancer, after chemotherapy and before surgery. This funding will allow us to work with Carrick Therapeutics, who is giving us a supply of drug for the clinical trial. Our ultimate goal is to offer a new targeted treatment option and hope to pancreatic cancer patients.

Mailing list button
Close Mailing List